Core signal
What: This review comprehensively summarized the clinical evidence and regulatory status of pediatric digital therapeutics (e.g., EndeavorRx).
PRO Summary
How to read this card
Evidence scope
Who: Children aged 8–17 with ADHD who participated in game-based attention training RCTs.
Use principle
Result: Attention test performance improved, but the effect size was moderate, and it is recommended as a complementary option to existing treatments.
Evidence Reading
What to check when interpreting the evidence
Study typeType: Other (Narrative Review)
PopulationTarget: Children with ADHD aged 8–17
EvidenceGrade: C
UseResult: Attention test performance improved, but the effect size was moderate, and it is recommended as a complementary option to existing treatments.
Consultation Prep
Turn the card into questions before consultation
FDA-approved digital therapeutics (EndeavorRx) are classified as medical devices and require a specialist consultation before use.
Record this as a question or context point before professional consultation.
Note that general educational game apps are different from FDA-approved digital therapeutics.
Record this as a question or context point before professional consultation.
Digital therapeutics are recommended as a supplement to existing treatments (medication, behavioral therapy).
Record this as a question or context point before professional consultation.
Limits
PRO use principles
Evidence scope
Limitations: This is a narrative review that does not meet systematic review criteria. Evidence for digital therapeutics beyond EndeavorRx is still limited. Long-term effects have not been confirmed.
Hold individual application
Do not transfer group-level findings or review summaries directly to an individual case without considering family context, school context, comorbidity, and professional guidance.
Use principle
Disclaimer: This summary is for informational purposes only. Consult a specialist before using any digital therapeutics.
Professional consultation
Diagnosis, treatment, medication, supplement use, digital therapeutics, educational planning, and ADHD management should be discussed with qualified professionals.
Scope Note
Notice and limits
Limitations: This is a narrative review that does not meet systematic review criteria. Evidence for digital therapeutics beyond EndeavorRx is still limited. Long-term effects have not been confirmed.
Disclaimer: This summary is for informational purposes only. Consult a specialist before using any digital therapeutics.